Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States: A Cohort Study
- PMID: 28672282
- DOI: 10.7326/M16-2733
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States: A Cohort Study
Abstract
Background: Clostridium difficile infection (CDI), the most common health care-associated infection, often recurs. Fecal microbiota transplantation is increasingly used to treat multiply recurrent CDI (mrCDI).
Objective: To determine whether the incidence of mrCDI is increasing in proportion to CDI and to identify risk factors for mrCDI.
Design: Retrospective cohort study.
Setting: United States.
Participants: 38 911 718 commercially insured patients in the OptumInsight Clinformatics Database, of whom 45 341 developed CDI.
Measurements: Age- and sex-standardized incidence rates for CDI and mrCDI.
Results: From 2001 to 2012, the annual incidence of CDI and mrCDI per 1000 person-years increased by 42.7% (from 0.4408 to 0.6289 case) and 188.8% (from 0.0107 to 0.0309 case), respectively. The increase in mrCDI incidence was independent of known risk factors for CDI. Those who developed mrCDI were older (median age, 56.0 vs. 49.0 years; adjusted odds ratio [aOR] per 10-year increase in age, 1.25 [95% CI, 1.21 to 1.29]) and were more likely to be female (63.8% vs. 58.7%; aOR, 1.24 [CI, 1.11 to 1.38]) and to have used antibiotics (72.3% vs. 58.8%; aOR, 1.79 [CI, 1.59 to 2.01]), proton-pump inhibitors (24.6% vs. 18.2%; aOR, 1.14 [CI, 1.01 to 1.29]), or corticosteroids (18.3% vs. 13.7%; aOR, 1.15 [CI, 1.00 to 1.32]) within 90 days of CDI diagnosis. Chronic kidney disease (10.4% vs. 5.6%; aOR, 1.49 [CI, 1.24 to 1.80]) and diagnosis in a nursing home (2.1% vs. 0.6%; aOR, 1.99 [CI, 1.34 to 2.93]) were also associated with increased risk for mrCDI.
Limitation: The primary analyses included only commercially insured patients in the United States.
Conclusion: Relative to CDI, mrCDI incidence has disproportionately increased, indicating a rising demand for mrCDI therapies.
Primary funding source: National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Allergy and Infectious Diseases.
Comment in
-
Fool Me Thrice: The Evolving Story of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2017 Aug 1;167(3):202-203. doi: 10.7326/M17-1565. Epub 2017 Jul 4. Ann Intern Med. 2017. PMID: 28672286 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):307. doi: 10.7326/L17-0600. Ann Intern Med. 2018. PMID: 29459963 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):307-308. doi: 10.7326/L17-0601. Ann Intern Med. 2018. PMID: 29459964 No abstract available.
-
Increasing Incidence of Multiply Recurrent Clostridium difficile Infection.Ann Intern Med. 2018 Feb 20;168(4):308. doi: 10.7326/L17-0602. Ann Intern Med. 2018. PMID: 29459965 No abstract available.
Similar articles
-
Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation.Clin Gastroenterol Hepatol. 2022 Apr;20(4):806-816.e6. doi: 10.1016/j.cgh.2020.12.004. Epub 2020 Dec 8. Clin Gastroenterol Hepatol. 2022. PMID: 33307184 Free PMC article.
-
Fecal microbiota transplantation and Clostridioides difficile infection among privately insured patients in the United States.J Gastroenterol. 2022 Jan;57(1):10-18. doi: 10.1007/s00535-021-01822-y. Epub 2021 Sep 8. J Gastroenterol. 2022. PMID: 34495400
-
Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes.AIDS. 2013 Nov 13;27(17):2799-807. doi: 10.1097/01.aids.0000432450.37863.e9. AIDS. 2013. PMID: 23842125 Free PMC article.
-
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.BMC Infect Dis. 2021 May 19;21(1):456. doi: 10.1186/s12879-021-06147-y. BMC Infect Dis. 2021. PMID: 34016040 Free PMC article.
-
Clostridioides difficile infection: a comprehensive review for primary providers.Rom J Intern Med. 2021 Aug 26;59(3):262-269. doi: 10.2478/rjim-2021-0010. Print 2021 Sep 1. Rom J Intern Med. 2021. PMID: 33713592 Review.
Cited by
-
Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study.Therap Adv Gastroenterol. 2020 Jul 27;13:1756284820942621. doi: 10.1177/1756284820942621. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32782480 Free PMC article.
-
Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis.Ther Adv Infect Dis. 2022 Apr 29;9:20499361221095679. doi: 10.1177/20499361221095679. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 35510091 Free PMC article.
-
Murine Intrarectal Instillation of Purified Recombinant Clostridioides difficile Toxins Enables Mechanistic Studies of Pathogenesis.Infect Immun. 2021 Mar 17;89(4):e00543-20. doi: 10.1128/IAI.00543-20. Print 2021 Mar 17. Infect Immun. 2021. PMID: 33468584 Free PMC article.
-
Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study.Clin Gastroenterol Hepatol. 2022 Aug;20(8):1739-1747. doi: 10.1016/j.cgh.2021.02.005. Epub 2021 Feb 5. Clin Gastroenterol Hepatol. 2022. PMID: 33549872 Free PMC article.
-
Vowst's FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection.Ann Med Surg (Lond). 2023 Oct 17;85(12):5852-5854. doi: 10.1097/MS9.0000000000001410. eCollection 2023 Dec. Ann Med Surg (Lond). 2023. PMID: 38098563 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources